Lakefront Biotherapeutics (GLPGF) Change in Account Payables (2015 - 2022)

Lakefront Biotherapeutics (GLPGF) has reported Change in Account Payables for 8 consecutive years, with -$8.3 million the latest figure, recorded in Q4 2022.

• On a quarterly basis, Change in Account Payables fell 1.49% year-over-year to -$8.3 million in Q4 2022; TTM through Dec 2022 was -$91.5 million, a 64.6% decrease from a year earlier, with the FY2025 full-year figure at -$3.7 million, up 30.61% from the prior year.
• Change in Account Payables was -$8.3 million for Q4 2022 at Lakefront Biotherapeutics, down from -$8.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $96.0 million in Q3 2019 and troughed at -$67.5 million in Q2 2020.
• A 5-year average of $3.2 million and a median of -$5.6 million in 2019 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables tumbled 98641.59% in 2019 and jumped 2393.67% in 2020, its largest moves.
• Over 5 years, Change in Account Payables stood at -$5707.0 in 2018, then sank by 98641.59% to -$5.6 million in 2019, then slumped by 32.17% to -$7.4 million in 2020, then slipped by 10.43% to -$8.2 million in 2021, then slipped by 1.49% to -$8.3 million in 2022.
• The last three Change in Account Payables figures came in at -$8.3 million (Q4 2022), -$8.2 million (Q4 2021), and -$7.4 million (Q4 2020), per Business Quant data.